ATTEST-2 Trial — Comparing Tenecteplase and Alteplase for Acute Stroke Management Introduction In recent years, the quest for optimal treatments for acute ischemic stroke has intensified, with the goal of improving outcomes and accessibility of care. The ATTEST-2 trial, published … Read More
Clinical Trials at your Fingertips!
Revolutionizing Medical Reference with Quick, Accessible Summaries of Landmark Clinical Trials - Right at Your Fingertips.
Latest Clinical Trials
ACE-PROTAVI Trial: Protamine Administration for Bleeding in TAVR
The Impact of Routine Protamine Administration in Transcatheter Aortic Valve Implantation (TAVI): Insights from the ACE-PROTAVI Trial As advancements in heart valve interventions continue, minimizing post-procedural complications remains a top priority for healthcare professionals. One area of growing interest is … Read More
TRAIN Trial: Transfusion Strategy in Acute Brain Injury
Understanding the TRAIN Trial: Transfusion Strategies in Patients with Acute Brain Injury In 2024, a groundbreaking study called the TRAIN Trial explored the impact of different transfusion strategies in patients suffering from acute brain injuries. This large, pragmatic, phase 3 … Read More
REDOX Trial: O2 for 24 Hours in Hypoxemia
REDOX Trial: Long-Term Oxygen Therapy for 24 or 15 Hours per Day in Severe Hypoxemia The REDOX trial is a phase IV, registry-based, randomized controlled study that examines whether long-term oxygen therapy (LTOT) for 24 hours per day provides better … Read More
BARACK-D Trial: Spironolactone in CKD
BARACK-D Trial: Low-Dose Spironolactone and Cardiovascular Outcomes in Moderate Stage Chronic Kidney Disease The BARACK-D trial is a prospective, randomized, open, blinded endpoint study that investigates the effects of low-dose spironolactone in patients with stage 3b chronic kidney disease (CKD) … Read More
GLAGOV Trial: Evolocumab on CAD Progression
GLAGOV Trial: Effect of Evolocumab on Coronary Disease Progression in Statin-Treated Patients The GLAGOV trial is a double-blind, placebo-controlled, randomized study designed to assess the impact of PCSK9 inhibition with evolocumab on the progression of coronary atherosclerosis in patients already … Read More
AMBASSADOR Trial: Adjuvant Pembrolizumab in Urothelial Carcinoma
The AMBASSADOR trial is a phase 3 randomized clinical trial aimed at evaluating whether pembrolizumab as adjuvant therapy is more effective than observation in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery. Study Details: Inclusion Criteria: Primary Outcome: Secondary … Read More
2R2 Trial: High-Dose, Short-Duration Rifampicin for TB Prevention
Published in: The LancetAuthors: Ruslami R et al.Publication Year: 2024Source: The Lancet, DOI: 10.1016/S2213-2600(24)00076-6 Objective of the Study:The 2R2 Trial was conducted to compare the safety and treatment completion rates of different doses and durations of rifampicin in patients who … Read More
LMS04 Trial: Doxorubicin-Trabectedin in Leiomyosarcoma
LMS04: Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma Published in: New England Journal of MedicineAuthors: Pautier P et al.Publication Year: 2024Source: N Engl J Med 2024; 391:789-799 Objective of the Study:This trial, LMS04, aimed to refine the treatment strategy for patients … Read More